SEC Form 4 · accession 0001394548-17-000011
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J Knapp
Officer — General Counsel
Period of report
Feb 6, 2017
Accepted (ET)
Feb 7, 2017 · 4:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $1.41 | Feb 6, 2017 | A | 10,000 | A | — | Feb 6, 2027 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1Granted pursuant to the Issuer's 2016 Incentive Plan.
- F2This stock option will vest in equal, monthly installments over 8 months beginning May 1, 2017 through December 31, 2017, so long as the Reporting Person remains in the company's continuous employ through the vesting period.